[1]
R. Lauppe, F. O. L. Nilsson, H. Fues Wahl, M. Lilja, A. Vikström, and S. T. Asanin, “Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration – a Swedish nationwide retrospective study”, AO, vol. 61, no. 11, pp. 1354–1361, Nov. 2022.